Tecentriq (Atezolizumab) vs Exkivity (mobocertinib)

Tecentriq (atezolizumab) is an immune checkpoint inhibitor that works by blocking the PD-L1 protein, which can help the body's immune system attack cancer cells, and is primarily used in the treatment of certain types of lung cancer, bladder cancer, and triple-negative breast cancer. Exkivity (mobocertinib) is a tyrosine kinase inhibitor that targets EGFR mutations, specifically designed for the treatment of non-small cell lung cancer (NSCLC) with specific mutations known as EGFR exon 20 insertion mutations. When deciding between the two, it is essential to consider the specific type of cancer and its molecular profile, as Tecentriq's effectiveness is influenced by PD-L1 expression and tumor mutational burden, while Exkivity is tailored for cancers with the aforementioned EGFR mutations.

Difference between Tecentriq and Exkivity

Metric	Tecentriq (Atezolizumab)	Exkivity (mobocertinib)
Generic name	Atezolizumab	Mobocertinib
Indications	Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer	Non-small cell lung cancer with EGFR Exon20 insertion mutations
Mechanism of action	PD-L1 inhibitor, immune checkpoint inhibitor	Tyrosine kinase inhibitor
Brand names	Tecentriq	Exkivity
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, nausea, infections, decreased appetite, dyspnea, cough, etc.	Diarrhea, rash, nausea, vomiting, decreased appetite, etc.
Contraindications	None known specifically; use caution in patients with immune-mediated side effects	None known specifically; use caution in patients with cardiac dysfunction
Drug class	Monoclonal antibody, Immune checkpoint inhibitor	Tyrosine kinase inhibitor
Manufacturer	Genentech (Roche)	Takeda Oncology

Efficacy

Efficacy of Tecentriq (Atezolizumab) in Lung Cancer

Tecentriq (Atezolizumab) is an immune checkpoint inhibitor specifically targeting the PD-L1 protein, which is used in the treatment of various types of cancer, including lung cancer. In non-small cell lung cancer (NSCLC), Tecentriq has shown a significant improvement in overall survival when used as a monotherapy in patients with high PD-L1 expression. Additionally, when combined with chemotherapy, Tecentriq has demonstrated an increase in progression-free survival in patients with metastatic non-squamous NSCLC, regardless of PD-L1 expression. The efficacy of Tecentriq has been established through multiple clinical trials, leading to its approval for first-line treatment of certain patients with NSCLC.

In small cell lung cancer (SCLC), Tecentriq has been studied in combination with chemotherapy (etoposide and either carboplatin or cisplatin) as a first-line treatment. The addition of Tecentriq to chemotherapy has been shown to significantly improve overall survival compared to chemotherapy alone. This has provided a new treatment option for patients with extensive-stage SCLC, a condition that has been historically difficult to treat effectively.

Efficacy of Exkivity (Mobocertinib) in Lung Cancer

Exkivity (Mobocertinib) is a tyrosine kinase inhibitor that has been specifically developed for the treatment of NSCLC with a mutation in the epidermal growth factor receptor (EGFR) exon 20 insertion. This mutation is relatively rare and has been associated with resistance to other EGFR-targeted therapies. Exkivity has shown promising results in clinical trials, leading to its approval for use in patients with this specific mutation who have received prior platinum-based chemotherapy.

The efficacy of Exkivity in this patient population has been demonstrated through its ability to achieve a meaningful objective response rate (ORR) and a duration of response (DOR) in patients who have exhausted other treatment options. The ORR reflects the proportion of patients who experience a significant reduction in tumor size, while the DOR indicates the length of time the response is maintained. These efficacy endpoints suggest that Exkivity offers a valuable new treatment option for patients with EGFR exon 20 insertion mutation-positive NSCLC.

Regulatory Agency Approvals

Tecentriq

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Exkivity

Food and Drug Administration (FDA), USA

Access Tecentriq or Exkivity today

If Tecentriq or Exkivity are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tecentriq

Buy Exkivity

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: